Clik here to view.
Astellas taps Poseida for second CAR-T deal focused on solid tumors
Astellas Pharma is signing Poseida Therapeutics to a second deal focused on developing off-the-shelf solid tumor cell therapies after the companies first teamed up in 2023. Gary Starling An Astellas...
View ArticleEditas, BMS extend T cell deal; KalVista seeks partner for preclinical HAE...
Plus, news about Novo Holdings, Pepper Bio, G1 Therapeutics and Akari: Editas, Bristol Myers Squibb add two years to T cell pact: The companies are extending a research deal for gene-edited alpha-beta...
View ArticleClik here to view.
GSK expedites Blenrep timelines as it eyes second chance in multiple myeloma
GSK wants to present Blenrep to regulatory bodies sooner. The UK pharma will submit Blenrep in second-line multiple myeloma to US, European and Japanese authorities in the second half of 2024, which is...
View ArticleIs UnitedHealth Group too big? Senators grill CEO on key question in wake of...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Senators questioned UnitedHealth Group CEO Andrew Witty for more than two hours on Tuesday over the...
View ArticleSenator alleges GSK is shirking its commitment to lower inhaler costs
Sen. Maggie Hassan (D-NH) is pressuring GSK to put a commonly used pediatric inhaler back on the market after the company stopped producing it in late 2023 in favor of an authorized generic version. In...
View ArticleClik here to view.
Pfizer sticks to the script in first-quarter update as cost cuts are 'largely...
The Covid-era swagger is gone. The cost cuts are mostly done. The executives are “cautiously optimistic.” And the stock is up. On Wednesday, Pfizer stayed away from some of its bolder promises of...
View ArticleJ&J follows Bristol Myers in appeal of judge's ruling against companies in...
Days after a New Jersey federal judge tossed their lawsuits against the Inflation Reduction Act, Johnson & Johnson has followed Bristol Myers Squibb and filed an appeal. As Bristol Myers did on...
View ArticleCVS is getting pummeled by the very strategy it once planned its future on
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) CVS Health on Wednesday reported that it’s been hit hard by higher medical costs. It led the company to...
View ArticleEpigenetic editing startup Chroma lays off staff, focusing on reaching the...
Chroma Medicine laid off an undisclosed number of employees earlier this week, as the privately held startup focuses its resources on moving its first epigenetic editors into human testing. The...
View ArticleClik here to view.
FDA decision on Sarepta’s Duchenne gene therapy could come earlier than expected
Sarepta Therapeutics’ chief scientist suggested that the FDA was ahead of schedule in reviewing the company’s application to expand the label of its Duchenne muscular dystrophy gene therapy Elevidys....
View ArticleClik here to view.
Novo’s GLP-1 sales boost profits, yet full potential still curbed by supply...
Novo Nordisk is still hitting a glass ceiling in revenues due to GLP-1 supply constraints even as sales keep rising. The price of Wegovy dropped in the first quarter, a trend that the company expects...
View ArticleClik here to view.
Spark co-founder launches new CNS gene therapy startup Latus Bio with $54M
Jang-Ho Cha had no interest in leaving his post at Novartis, where he led translational medicine for the pharma giant’s work in neuroscience. But in the summer of 2022, he received a call from a leader...
View ArticleA once-public psychedelic biotech reemerges with $103M from MPM and Novo...
MPM BioImpact and Novo Holdings are among a group of investors pouring $103 million into a psychedelic biotech that MPM took private last summer. Reunion Neuroscience, a Morristown, NJ-based biotech,...
View ArticleClik here to view.
BridgeBio spins out oncology unit with $200M in backing for RAS assets
BridgeBio, a biotech known for its model of setting up subsidiaries to house its R&D programs, is splitting off its oncology unit with $200 million in support from 11 investors. Cormorant Asset...
View ArticleClik here to view.
Biotech vets raise $67M to develop targeted activators for cancer
Delphia Therapeutics said Thursday that it raised $67 million to develop targeted cancer therapies that overactivate drivers of cancer, defying the norm established by decades of cancer drug...
View ArticleClik here to view.
Novartis makes a $1B radiopharma deal, buying Mariana Oncology
Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series B. The move, which...
View ArticleClik here to view.
As it cuts costs and pipeline, Bristol Myers hands back a cancer drug to...
Bristol Myers Squibb will give back a preclinical cancer drug to Schrödinger, returning the SOS1 inhibitor that was part of a 2020 deal between the companies. Chris Boerner The move is part of a...
View ArticleContext Therapeutics' $100M placement; Blueprint raises guidance for rare...
Plus, news about Novocure and Corvus: Context Therapeutics’ $100M PIPE: Nextech led the private placement, and other investors like Ally Bridge Group took part. The solid tumor biotech also said the...
View ArticleAvid Bio fielding client inquiries due to China bill; Oxford Bio wants to...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Avid Bioservices has detected an uptick in client interest in the...
View ArticleFDA asks for more data on Dupixent in COPD in move that could delay a decision
The FDA wants more info on Regeneron and Sanofi’s blockbuster Dupixent before it decides whether to approve the treatment for some patients with chronic obstructive pulmonary disease, or COPD. That...
View Article